Jama Pitman - 18 Jan 2022 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc.

Role
Title: SVP, Regulatory, Quality, & Portfolio Management
Signature
/s/ Jeffrey Held, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
18 Jan 2022
Net transactions value
$0
Form type
4
Filing time
20 Jan 2022, 16:00:21 UTC
Previous filing
17 Dec 2021
Next filing
18 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Award $0 +13,667 +54% $0.000000 39,105 18 Jan 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DCPH Stock Option (Right to Buy) Award $0 +54,667 $0.000000 54,667 18 Jan 2022 Common Stock 54,667 $8.27 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person was awarded 13,667 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock. The RSUs shall vest in three (3) equal annual installments on each of January 15, 2023, January 15, 2024 and January 15, 2025.
F2 This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four (4) years, beginning on February 18, 2022.

Remarks:

Title: SVP, Regulatory, Quality, & Portfolio Management